CRIS Current Research Information System

MARCONI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.319
NA - Nord America 4.445
EU - Europa 3.377
AF - Africa 356
SA - Sud America 286
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 13.802
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.367
CN - Cina 1.637
SG - Singapore 1.525
VN - Vietnam 1.092
IT - Italia 738
GB - Regno Unito 721
SE - Svezia 419
DE - Germania 412
HK - Hong Kong 322
KR - Corea 260
BR - Brasile 216
IN - India 215
NL - Olanda 196
RU - Federazione Russa 159
FR - Francia 147
IE - Irlanda 126
FI - Finlandia 102
CI - Costa d'Avorio 93
TG - Togo 91
JP - Giappone 64
ZA - Sudafrica 59
NG - Nigeria 57
BG - Bulgaria 50
CA - Canada 49
SC - Seychelles 49
EE - Estonia 48
JO - Giordania 45
BE - Belgio 42
ID - Indonesia 41
CH - Svizzera 40
AR - Argentina 34
UA - Ucraina 31
AT - Austria 28
ES - Italia 28
PL - Polonia 25
IR - Iran 20
MX - Messico 19
GR - Grecia 16
TR - Turchia 16
BD - Bangladesh 13
LT - Lituania 13
UZ - Uzbekistan 12
EC - Ecuador 10
IQ - Iraq 9
AU - Australia 8
HR - Croazia 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
EU - Europa 6
RO - Romania 6
CO - Colombia 5
MK - Macedonia 5
NZ - Nuova Zelanda 4
PE - Perù 4
AL - Albania 3
EG - Egitto 3
KZ - Kazakistan 3
LB - Libano 3
PH - Filippine 3
PK - Pakistan 3
PT - Portogallo 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
VE - Venezuela 3
CZ - Repubblica Ceca 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
LV - Lettonia 2
MA - Marocco 2
MY - Malesia 2
NP - Nepal 2
RS - Serbia 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GY - Guiana 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 13.798
Salva come PNG Salva come JPEG
Città #
Singapore 1.059
Dong Ket 639
Southend 631
Ashburn 610
Hefei 529
Chandler 438
Hong Kong 317
Ann Arbor 292
Fairfield 264
Seoul 258
Beijing 201
Santa Clara 157
Houston 154
Bologna 149
Wilmington 145
Boardman 137
Woodbridge 137
Seattle 136
Dallas 129
Dublin 125
Princeton 118
Cambridge 109
Abidjan 93
Lomé 91
New York 90
Hanoi 86
Ho Chi Minh City 78
Los Angeles 77
Milan 62
Tokyo 58
Helsinki 55
Munich 52
Nanjing 51
Sofia 50
Westminster 50
Bengaluru 47
Amman 45
Medford 43
Padova 43
Redondo Beach 43
Abeokuta 41
Brussels 41
Buffalo 40
São Paulo 36
Berlin 33
Bremen 33
Jakarta 31
Redmond 30
Redwood City 30
Shanghai 29
Bern 28
Frankfurt am Main 28
Rome 28
Lappeenranta 27
Guangzhou 26
Shenyang 25
Turin 25
Jinan 23
Nuremberg 23
Toronto 23
Falkenstein 21
Florence 21
London 21
Saint Petersburg 21
Zhengzhou 21
Hebei 20
San Diego 20
Tianjin 20
Phoenix 19
Turku 19
Vienna 18
Nanchang 17
Changsha 16
Chicago 16
Tongling 16
Warsaw 15
Jiaxing 14
Biên Hòa 13
Chengdu 13
Brooklyn 12
Castel Maggiore 12
Chennai 12
Haiphong 12
Hyderabad 12
Montreal 12
Paris 12
Atlanta 11
Stockholm 11
Wuhan 11
Hangzhou 10
San Francisco 10
Shijiazhuang 10
Xi'an 10
Amsterdam 9
Busseto 9
Falls Church 9
Manchester 9
Ninh Bình 9
Orem 9
Quận Bình Thạnh 9
Totale 9.009
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 337
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 278
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 271
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 260
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 242
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 232
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 219
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 215
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 213
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 210
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 202
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 201
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 197
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 193
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 189
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 186
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 177
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 172
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 169
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 169
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 168
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 168
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 167
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 164
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 161
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 157
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 153
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 152
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 151
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 151
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 149
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 147
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 146
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 146
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 145
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 141
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 139
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 139
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 135
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 133
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 133
SNP array reveals a new deletion of JAK2 in AML patients 133
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 132
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 132
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 131
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 131
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 128
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 127
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 127
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 126
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 125
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 124
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 124
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 124
Novel insights and therapeutic approaches in secondary AML 121
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 121
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) 119
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 118
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 117
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 116
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 112
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 108
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 107
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 105
Safety of FLT3 inhibitors in patients with acute myeloid leukemia 104
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 103
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 102
Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey 101
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 100
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies 98
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 96
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 95
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 95
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 90
Biological therapy in elderly patients with acute myeloid leukemia 89
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 86
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 86
Editorial: Precision medicine for acute myeloid leukemia 81
Personalizing precision medicine: Patients with AML perceptions about treatment decisions 78
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia 75
Hemophagocytic lymphohistiocytosis in gastric cancer: A rare syndrome for the oncologist. Case report and brief review 69
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 67
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 61
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS 50
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 49
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia 48
Issue highlights—November 2024 39
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia 37
Expert consensus guideline on the diagnosis of type 1 Gaucher disease in adult patients 36
Acute myeloid leukemia mutations: Therapeutic implications 34
Totale 14.025
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.945
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.176 0 0 0 0 0 62 33 93 96 34 84 774
2021/20221.502 160 35 70 145 129 72 46 120 76 105 305 239
2022/20231.834 206 261 96 222 164 134 60 96 310 49 139 97
2023/2024669 22 66 48 71 31 139 61 65 42 46 49 29
2024/20252.836 88 369 207 187 220 103 378 127 34 278 244 601
2025/20264.042 817 877 624 725 709 290 0 0 0 0 0 0
Totale 14.138